It's a mitochondria-targeted prodrug (~930 g/mol) that attacks cancer cells on four fronts simultaneously: a TPP⁺ warhead that homes in on cancer's abnormally high mitochondrial voltage, a pH-sensitive linker that only activates in the acidic tumor environment, a Complex I inhibitor that cuts off the cell's energy supply, and a ROS amplifier that floods it with toxic free radicals — while a glycolysis blocker removes the backup escape route.
- Citation du texte
- Logan Leatherman (Auteur), 2026, Apollumi-930: A Novel Multi-Mechanism Mitochondrial-Targeted Cancer Therapeutic with Triple Selectivity and Immunogenic Cell Death Activation, Munich, GRIN Verlag, https://www.grin.com/document/1711589
Lire l'ebook
